Adaptive Biotechnologies is trading 4.2% down at $20.89 as investors consolidate gains following a sharp rally driven by its $300 million convertible notes offering and business separation plans.
- The recent upside was fueled by the pricing of an upsized $300 million 0% convertible senior notes offering and bullish analyst sentiment.
- Shares are pulling back after a significant run-up in the prior session, which saw increased price targets following the notes deal.
- No new company-specific headlines or broader sector shocks have emerged during the July 10, 2026, trading session.